Tirzepatide Half-Life: How Long It Stays in Your System
How long Tirzepatide stays in the body, how that shapes dosing frequency, and what is known about drug testing.
- Half-life
- approximately 5 days
- subcutaneous, in people · FDA label (Mounjaro)
- Dosing interval
- Varies by study
- as used in studies
- WADA
- Not listed
- 2026 Prohibited List
- Detection window
- Not found
- None reported as of 2 Oct 2026
Tirzepatide half-life
A half-life depends on the route (under the skin, into a vein, by mouth or nasal spray) and the species it was measured in, so we report each value with its route and source.
| Route | Half-life | Measured in | Source |
|---|---|---|---|
| subcutaneous | approximately 5 days | People | FDA label (Mounjaro) |
| subcutaneous | approximately 5-6 days | People | FDA label (Zepbound) |
| subcutaneous | ~5 days (population PK, 19 pooled studies) | People | PMID 38356317 |
What half-life means
Half-life is the time it takes for the amount of a drug in the blood to fall by half. After one half-life, about 50% is left; after two, about 25%; after four to five, only a few percent remain.
- A long half-life lets a drug be dosed less often, for example once a week.
- A short half-life means levels rise and fall quickly, which is why some peptides are given daily or more often.
- Effects can outlast blood levels, so half-life alone does not tell you how long a drug works.
What it means for dosing frequency
Dosing intervals used in published studies of Tirzepatide:
- once weekly, subcutaneous (Human controlled trial; The New England journal of medicine 2025, PMID 40353578)
- weekly, subcutaneous (Human RCT; The New England journal of medicine 2025, PMID 41406444)
- once per week, subcutaneous (Human RCT; The New England journal of medicine 2025, PMID 39555826)
- weekly (Human controlled trial; Reproductive biology and endocrinology 2025, PMID 40604795)
Changing the interval changes how much drug builds up between doses, so it is not a free choice.
Drug tests and sport
Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.
Anti-doping labs use tests built for specific substances. Whether a given test detects Tirzepatide, and for how long, is not reported in the anti-doping literature we checked (as of 2 Oct 2026).
Common questions
How long does Tirzepatide stay in your system?
Its reported half-life is approximately 5 days (subcutaneous); approximately 5-6 days (subcutaneous). Most of a dose is gone after about four to five half-lives.
What is the half-life of Tirzepatide?
Approximately 5 days (subcutaneous); approximately 5-6 days (subcutaneous), from the sources cited below.
Is Tirzepatide on the WADA prohibited list?
No, it is not listed. GLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.
More on Tirzepatide
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 3These highlights do not include all the information needed to use ZEPBOUND safely and effectively. See full prescribing information for ZEPBOUND. ZEPBOUND ® (tirzepatide) Injection, for subcutaneous uFDA label (Zepbound), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 4Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide.CPT: pharmacometrics & systems pharmacology · 2024PMID 38356317Accessed 2 Oct 2026
- 5Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
- 6Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.The New England journal of medicine · 2025PMID 41406444Accessed 2 Oct 2026
- 7Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.The New England journal of medicine · 2025PMID 39555826Accessed 2 Oct 2026
- 8Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obesity: a controlled pilot study.Reproductive biology and endocrinology : RB&E · 2025PMID 40604795Accessed 2 Oct 2026
Found an error? Report a correction.